OtherPublished 23 Jul 2016
Ruxolitinib for patients with polycythemia vera who have had an inadequate response or are intolerant to hydroxyurea: a critical appraisal
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The goal of this review is to critically analyze data supporting the use of ruxolitinib in polycythemia vera patients resistant or intolerant to hydroxyurea. We analyzed the randomized Phase III study (RESPONSE) and we applied the Grading of Evidence, Assessment, Development and Evaluation approach by evaluating five dimensions of evidence: overall risk of bias, imprecision, inconsistency, indirectness and publication bias. We upgraded the quality of evidence because of large effect size on splenomegaly, hematocrit and symptoms but we downgraded it for performance bias and for indirectness of the comparator. In conclusion, by identifying factors affecting the quality of evidence, we rated the outcomes of ruxolitinib in polycythemia vera patients resistant or intolerant to hydroxyurea as having moderate level of evidence.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalClinical Investigation
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Giovanni Barosi”